New York Vioxx suit
The state and city of New York file a joint lawsuit against Merck claiming company committed Medicaid fraud by concealing the drug's cardiovascular risks. The Sept. 17 complaint seeks damages and recovery of the millions of dollars the state spent on prescriptions for rofecoxib from its introduction in 1999 until its withdrawal in 2004. Merck says that it "acted within a week after one of its own studies suggested, for the first time, an increased relative risk with Vioxx compared to placebo." Merck is facing similar suits from attorneys general in six other states...
You may also be interested in...
A provisional list of CBD products that can continue to legally be sold in the UK has been issued by the Food Standards Agency. However the list currently only includes products from three suppliers and will not be complete until June 2021, meaning the vast majority of companies face a nervy wait.
The Advancing Education on Biosimilars Act and the Ensuring Innovation Act will be looked at by the US President Joe Biden, after receiving the approval of both the Senate and the House of Representatives. The bills are aimed at lowering prescription drug costs and saving overall healthcare costs.
Lotus Pharmaceuticals aims to build a stronghold in Thailand and beyond, after the Alvogen subsidiary announced a partnership with a subsidiary of Thai state-owned conglomerate PTT, which includes a $50m capital injection.